RGT Stock Overview
A multidisciplinary drug development Company, engages in the provision of medicines targeting immunology and neurology worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Argent BioPharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.17 |
| 52 Week High | AU$0.55 |
| 52 Week Low | AU$0.16 |
| Beta | 1.15 |
| 1 Month Change | -35.85% |
| 3 Month Change | -65.66% |
| 1 Year Change | n/a |
| 3 Year Change | -99.61% |
| 5 Year Change | -99.54% |
| Change since IPO | -99.35% |
Recent News & Updates
Recent updates
Shareholder Returns
| RGT | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | -35.8% | -1.4% | 1.5% |
| 1Y | n/a | -8.6% | 9.0% |
Return vs Industry: Insufficient data to determine how RGT performed against the Australian Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how RGT performed against the Australian Market.
Price Volatility
| RGT volatility | |
|---|---|
| RGT Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 10.1% |
| Market Average Movement | 8.0% |
| 10% most volatile stocks in AU Market | 16.7% |
| 10% least volatile stocks in AU Market | 3.0% |
Stable Share Price: RGT's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: Insufficient data to determine RGT's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | n/a | Roby Zomer | argentbiopharma.com |
Argent BioPharma Limited, a multidisciplinary drug development Company, engages in the provision of medicines targeting immunology and neurology worldwide. The company’s principal product candidates include CimetrA, which is in phase IIB clinical trial for the treatment of acute lung injury and ARDS; CannEpil, which is in phase I clinical trial for refractory epilepsy; and CogniCann, which is in phase IIA clinical trial for the symptomatic relief of Dementia and Alzheimer. It is also involved in the preclinical development of Irnican for the treatment of Glioblastoma Multiforme; and RGAI03MW01, which focuses on chronic wound treatment.
Argent BioPharma Limited Fundamentals Summary
| RGT fundamental statistics | |
|---|---|
| Market cap | AU$13.57m |
| Earnings (TTM) | -AU$17.53m |
| Revenue (TTM) | AU$891.08k |
15.2x
P/S Ratio-0.8x
P/E RatioIs RGT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RGT income statement (TTM) | |
|---|---|
| Revenue | AU$891.08k |
| Cost of Revenue | AU$1.20m |
| Gross Profit | -AU$304.15k |
| Other Expenses | AU$17.23m |
| Earnings | -AU$17.53m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.32 |
| Gross Margin | -34.13% |
| Net Profit Margin | -1,967.34% |
| Debt/Equity Ratio | -149.0% |
How did RGT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/08 09:23 |
| End of Day Share Price | 2025/01/02 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Argent BioPharma Limited is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Salvatore Gaetano Verdoliva | Canaccord Genuity |
| Robin Davison | Capital Network by Proactive Investors |
| Maxim Jacobs | Edison Investment Research |